Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rare disease clotting mystery probed in 57 patients

NCT ID NCT03560570

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study examined blood clotting in 57 people with Congenital Disorder of Glycosylation (CDG), a rare genetic condition. Researchers used a special test called the thrombin generation assay to see if the body's clotting system stays balanced despite having low levels of both clotting and anti-clotting proteins. The goal was to understand why some patients have bleeding or clotting problems, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

57 people

The number who actually took part.

Started

Jan 2014

Finished

Dec 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

CDG cohort comes from reference center of rares metabolic diseases of Necker-Enfants malades hospital in Paris

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: -Clinical diagnosis of Congenital Disorder of Glycosylation (CDG) Exclusion Criteria: \- no exclusion criteria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Congenital disorders of glycosylation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congenital disorder of glycosylation Hemorrhage thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Congenital disorders of glycosylation

Contacts and locations

Locations

  • Hôpital Necker Enfants malades

    Paris, Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.